DESTINY-Breast03 trial: some questions remain

Lancet. 2023 May 20;401(10389):1652. doi: 10.1016/S0140-6736(23)00679-7.

Author

Affiliation

¹ Department of Nuclear Medicine, Bordeaux University Hospital, Pessac 33604, France. Electronic address: elif.hindie@chu-bordeaux.fr.

PMID: 37210114
DOI: 10.1016/S0140-6736(23)00679-7

No abstract available

Publication types

Letter
Comment